

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Pazopanib for the first-line treatment of advanced and/or metastatic renal cell carcinoma

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (post-referral)

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<p>“Considering that immunotherapy is not a relevant comparator in this STA, the following manufacturers should be removed from the comparator manufacturers list.</p> <ul style="list-style-type: none"> • Novartis (aldesleukin) • Roche (interferon-alpha) • Schering-Plough (interferon-alpha)” 	GlaxoSmithKline		Noted	NICE believes that these are relevant comparators and therefore shall remain in the matrix.

2.	“The list of patient/carer group of consultees is enormous, is there such a list of religious/ethnic groups in case of offence at missing anyone out? Could this not be taken on by just the generic groups?”	Royal College of Nursing	Noted	As part of NICE’s commitment to promoting equality and diversity these groups have been identified and invited to become consultees within all Technology Appraisals. These specific groups meet the existing inclusion criteria in order to be added to this matrix.
3.	Remove Confederation of Indian Organisations from patient/carer group consultees.	NICE Secretariat	Removed	Confederation of Indian Organisations have now closed, and therefore been removed from the matrix.